World

Iranian diplomat urges U.S. to lift sanctions in effective manner

Nov 26, 2021

Tehran (Iran), November 26: A senior Iranian diplomat on Thursday urged the United States to lift anti-Iran sanctions in an "effective and verifiable manner," as the remaining parties to the 2015 nuclear deal are preparing to attend a meeting on the revival of the accord next week.
Mohammad Reza Ghaebi, the acting head of Iran's mission in Vienna, said that in order to end the current deadlock over the implementation of Iran's nuclear deal, formally known as the Joint Comprehensive Plan of Action (JCPOA), the U.S. government should "stop violating its obligations under the agreement without any delay and precondition," reported Iran's news network Press TV.
Making the remarks before the Board of Governors of the International Atomic Energy Agency (IAEA), Ghaebi cited "the U.S. violations of the agreement" and "the European countries' unwillingness to clearly condemn the U.S. illegal withdrawal from the JCPOA and the re-imposition of sanctions against Iran" as the root causes for the current impasse regarding the JCPOA.
Referring to the upcoming Vienna nuclear meeting, he noted "it is important that the outcome of these efforts ensures that all sanctions will be lifted in an effective and verifiable manner."
It is "not reasonable" to expect more forbearance from Iran as long as the sanctions remain in place, he stressed.
The U.S. government under former President Donald Trump withdrew from the 2015 agreement in May 2018 and unilaterally reimposed sanctions on Iran. In response, Iran gradually stopped implementing parts of its commitments to the deal in May 2019.
Source: Xinhua

More news

Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones

Mumbai (Maharashtra) [India], July 7: Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects Piramal Pharma's continued commitment to improving patient outcomes through science-led innovation, operational excellence and quality, while building a resilient global platform that serves customers across regulated markets worldwide.

Jul 07, 2026